Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis

Ying FENG; Ke SHI; Xiaohua ZHANG; Li YANG; Xianbo. WANG

doi:10.3969/j.issn.1001-5256.2022.07.015

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1534-1539

PDF( 2481 KB)

Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis

DOI: 10.3969/j.issn.1001-5256.2022.07.015

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

National Natural Science Foundation of China (82004153);

Beijing Science and Technology Project (Z191100006619033)

More Information

Corresponding author: WANG Xianbo, wangxianbo638@163.com (ORCID: 0000-0002-3593-5741)
Received Date: 2022-03-28
Accepted Date: 2022-05-02
Published Date: 2022-07-20

Abstract

Abstract

Objective To investigate the effect of anti-liver fibrosis traditional Chinese medicine (TCM) therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis (SMVT). Methods A retrospective analysis was performed for the clinical data of 231 patients with liver cirrhosis and SMVT who were hospitalized and treated in Beijing Ditan Hospital, Capital Medical University, from January 2017 to June 2020, and the patients were divided into TCM group with 114 patients and control group with 117 patients. In addition to the conventional treatment regimen for primary diseases, antithrombotic indications were fully evaluated, and standard antithrombotic treatment was applied if necessary; the patients in the TCM group were given anti-liver fibrosis TCM therapy for ≥6 months. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Cox regression model was used to analyze the independent influencing factors for prognosis; outcome events (death) were observed, the Kaplan-Meier method was used to plot survival curves, and the log-rank test was used for comparison; a stratified analysis based on Child score was performed to investigate the effect of anti-liver fibrosis TCM therapy on the prognosis of patients with different liver function grades and the effect of different anti-liver fibrosis TCM drugs on the prognosis of patients. Results The multivariate analysis showed that age (hazard ratio [HR]=1.039, 95% confidence interval [CI]: 1.001-1.078, P=0.041) and C-reactive protein (CRP) (HR=1.025, 95%CI: 1.009-1.041, P=0.003) were independent risk factors for death, while oral administration of anti-liver fibrosis TCM drugs was a protective factor (HR=0.148, 95%CI: 0.051-0.429, P=0.001). The survival curve analysis showed that the TCM group had a significantly higher survival rate than the control group (95.6% vs 81.2%, χ²=17.032, P < 0.0001), and further analysis showed that compared with the control group, the TCM group had significantly higher survival rates of the patients with Child-Pugh grade A/B liver function (Child-Pugh grade A: 100% vs 66.7%, χ²=4.003, P=0.045; Child-Pugh grade B: 96.7% vs 85.1%, χ²=10.788, P=0.002). There was no significant difference in the effect on the prognosis of patients between the three anti-liver fibrosis TCM drugs (P > 0.05). Conclusion Age and CRP are independent influencing factors for the prognosis of patients with liver cirrhosis and SMVT, and anti-liver fibrosis TCM therapy can reduce the mortality rate of patients, especially in the patients with Child-Pugh grade A/B liver function.
- Liver Cirrhosis,
- Mesenteric Veins,
- Venous Thromboembolism,
- Drugs, Chinese Herbal

FullText(HTML)

References(23)

References

[1]	JIANG M, LI CL, PAN CQ, et al. Nomogram for predicting transmural bowel infarction in patients with acute superior mesenteric venous thrombosis[J]. World J Gastroenterol, 2020, 26(26): 3800-3813. DOI: 10.3748/wjg.v26.i26.3800.
[2]	CHEN H, XIAO ZX. Diagnosis and treatment strategy of acute mesenteric venous thrombosis[J/CD]. Chin J Vasc Surg(Electronic Version), 2019, 11(1): 7-9. DOI: 10.3969/j.issn.1674-7429.2019.01.003. 陈浩, 肖占祥. 急性肠系膜静脉血栓形成的诊疗策略[J/CD]. 中国血管外科杂志(电子版), 2019, 11(1) : 7-9. DOI: 10.3969/j.issn.1674-7429.2019.01.003.
[3]	ZHANG FX. Modern strategies for the diagnosis and treatment of acute mesenteric ischemic disease[J]. Chin J Pract Surg, 2020, 40(12): 1373-1375. DOI: 10.19538/j.cjps.issn1005-2208.2020.12.08. 张福先. 急性肠系膜缺血性疾病诊治现代策略[J]. 中国实用外科杂志, 2020, 40(12): 1373-1375. DOI: 10.19538/j.cjps.issn1005-2208.2020.12.08.
[4]	DING N, ZHANG XF. Clinical analysis of decompensated liver cirrhosis complicated with acute mesenteric venous thrombosis[J]. J China Presc Drug, 2014, 11: 70-71. DOI: 10.3969/j.issn.1671-945X.2014.11.059. 丁宁, 张学峰. 失代偿期肝硬化合并急性肠系膜静脉血栓的临床分析[J]. 中国处方药, 2014, 11: 70-71. DOI: 10.3969/j.issn.1671-945X.2014.11.059.
[5]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[6]	NIU SS, ZHANG Q, HOU YX, et al. Primary preventive effect of anti-fibrosis treatment on esophageal and gastric varices bleeding in patients with cirrhosis: a real-world study[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006. 牛帅帅, 张群, 侯艺鑫, 等. 抗肝纤维化治疗对肝硬化食管胃静脉曲张出血的一级预防作用[J]. 中西医结合肝病杂志, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006.
[7]	LIU Q, XU X, WANG ZG. Effect of calycosin on intestinal mucosal barrier function in cirrhosis rats and its mechanism[J]. J Jilin Univ(Med Edit), 2022, 294(2): 391-398. DOI: 10.13481/j.1671-587X.20220216. 刘琦, 徐新, 王正根. 毛蕊异黄酮对肝硬化大鼠肠黏膜屏障功能的影响及其机制[J]. 吉林大学学报(医学版), 2022, 294(2): 391-398. DOI: 10.13481/j.1671-587X.20220216.
[8]	HOU YX, YANG ZY, YANG YY, et al. Clinical effect of Liqi Jianpi prescription in preventing hemorrhage within one year in patients with hepatitis B cirrho-sis and severe esophageal and gastric varices[J]. J Clin Hepatol, 2019, 35(4): 780-784. DOI: 10.3969/j.issn.1001-5256.2019.04.015. 侯艺鑫, 杨志云, 杨玉英, 等. 理气健脾方预防乙型肝炎肝硬化合并重度食管胃底静脉曲张患者1年内出血的疗效评价[J]. 临床肝胆病杂志, 2019, 35(4): 780-784. DOI: 10.3969/j.issn.1001-5256.2019.04.015.
[9]	WANG XB, LIU P, TANG ZP, et al. Cordyceps mycelia extract decreases portal hypertension in rats with dimethylnitrosamine-induced liver cirrhosis: a study on its histological basis[J]. J Chin Integr Med, 2008, 6(11): 1136-1144. DOI: 10.3736/jcim20081107. 王宪波, 刘平, 唐志鹏, 等. 冬虫夏草菌丝提取物降低二甲基亚硝胺大鼠肝硬化门静脉高压效应的组织学基础[J]. 中西医结合学报, 2008, 6(11): 1136-1144. DOI: 10.3736/jcim20081107.
[10]	LIU XN. Efficacy and safety analysis of acupuncture combined with traditional Chinese medicine in the treatment of sequelae of cerebral thrombosis[J]. Chin J Mod Drug Appl, 2021, 15(8): 197-199. DOI: 10.14164/j.cnki.cn11-5581/r.2021.08.078. 刘晓宁. 针灸联合中药治疗脑血栓后遗症的疗效及安全性分析[J]. 中国现代药物应用, 2021, 15(8): 197-199. DOI: 10.14164/j.cnki.cn11-5581/r.2021.08.078.
[11]	WANG ZC, GU EL, WANG SP, et al. Effect of alprostadil combined with traditional Chinese medicine Buyang Huanwu decoction in the treatment on liver cirrhosis with portal vein thrombosis[J]. J Emerg Tradit Chin Med, 2017, 26(2): 311-314. DOI: 10.3969/j.issn.1004-745X.2017.02.041. 王忠成, 顾尔莉, 王世蓬, 等. 前列地尔联合补阳还五汤治疗门静脉血栓症的疗效观察[J]. 中国中医急症, 2017, 26(2): 311-314. DOI: 10.3969/j.issn.1004-745X.2017.02.041.
[12]	WANG HX, HAN SN. Research progress of traditional Chinese medicine injection for blood-activating and stasis-resolving in the prevention and treatment of deep venous thrombosis[J]. China Modern Med, 2016, 23(6): 22-24. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201606009.htm 王惠霞, 韩世妮. 活血化瘀中药注射剂防治深静脉血栓形成的研究进展[J]. 中国当代医药, 2016, 23(6): 22-24. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201606009.htm
[13]	FAN WJ, HU XM, HUANG RY, et al. Chinese medicine injection for promoting blood circulation and removing blood stasis combined with low molecular heparin on postoperative DVT: an overview of systematic reviews[J]. J Emerg Tradit Chin Med, 2020, 29(8): 1356-1360. DOI: 10.3969/j.issn.1004-745X.2020.08.012. 樊炜静, 胡啸明, 黄仁燕, 等. 活血化瘀类中药注射剂联合低分子肝素防治术后深静脉血栓形成疗效和安全性的系统评价再评价[J]. 中国中医急症, 2020, 29(8): 1356-1360. DOI: 10.3969/j.issn.1004-745X.2020.08.012.
[14]	CHEN R, CHEN PP, LIN CC, et al. Comparison of mesenteric vascular ultrasound and CTA in the diagnosis of emergency acute mesenteric vascular embolism[J]. China Med Herald, 2021, 18(17): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202117029.htm 程瑞, 陈佩佩, 林姹姹, 等. 肠系膜血管超声与CTA对急诊急性肠系膜血管栓塞的诊断对比[J]. 中国医药导报, 2021, 18(17): 122-125. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202117029.htm
[15]	WANG QY, WU MF, LIU X, et al. Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021[J]. Chin J Clin Pharmacol, 2021, 37(21): 2999-3016. DOI: 10.13699/j.cnki.1001-6821.2021.21.032. 王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. DOI: 10.13699/j.cnki.1001-6821.2021.21.032.
[16]	YANG L, FENG Y, ZHOU GQ, et al. Clinical characteristics of 254 patients with chronic liver disease complicated with superior mesenteric vein embolism[J]. Mod Digest Interv, 2021, S1(26): 137-139. 杨莉, 冯颖, 周桂琴, 等. 254例慢性肝病并发肠系膜上静脉栓塞患者的临床特征分析[J]. 现代消化及介入诊疗, 2021, S1(26): 137-139.
[17]	LI X. Clinical thinking of Wang Xianbo in the treatment of hepatitis B cirrhosis[J]. Beijing J Tradit Chin Med, 2015, 34(9): 713-716. DOI: 10.16025/j.1674-1307.2015.09.011. 李向. 王宪波治疗乙型肝炎肝硬化的临证思路[J]. 北京中医药, 2015, 34(9): 713-716. DOI: 10.16025/j.1674-1307.2015.09.011.
[18]	JIANG Y. Preliminary discussion on blood stasis syndrome in Yilin Gaicuo[J]. J Beijing Univ Chin Med, 2014, 37(3): 152-155, 164. DOI: 10.3969/j.issn.1006-2157.2014.03.002. 蒋燕. 《医林改错》瘀血病证的初步探讨[J]. 北京中医药大学学报, 2014, 37(3): 152-155, 164. DOI: 10.3969/j.issn.1006-2157.2014.03.002.
[19]	GU SN, JIANG TW. Clinical application and experimental research progress of activating blood and removing stasis drugs for treating thrombotic diseases[J]. J Changchun Univ Chin Med, 2019, 35(2): 382-384, 388. DOI: 10.13463/j.cnki.cczyy.2019.02.053. 谷胜男, 姜彤伟. 活血化瘀药治疗血栓性疾病的临床应用及实验研究进展[J]. 长春中医药大学学报, 2019, 35(2): 382-384, 388. DOI: 10.13463/j.cnki.cczyy.2019.02.053.
[20]	LIU JL. Study on the antithrombotic effect of huoxue huayu drugs[J]. China Modern Med, 2013, 20(35): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201335007.htm 柳吉玲. 活血化瘀药抗血栓作用的研究进展[J]. 中国当代医药, 2013, 20(35): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201335007.htm
[21]	CHEN J, DENG J, ZHOU J, et al. Metabonomic study of traditi. onal Chinese herb pair, Qinghao-Biejia in treating systemic lupus erythematosus mice[J]. Chin Pharmacol Bull, 2016, 32(5): 727-731, 732. DOI: 10.3969/j.issn.1001-1978.2016.05.026. 陈娟, 邓军, 周佳, 等. 青蒿-鳖甲药对配伍治疗系统性红斑狼疮小鼠的代谢组学研究[J]. 中国药理学通报, 2016, 32(5): 727-731, 732. DOI: 10.3969/j.issn.1001-1978.2016.05.026.
[22]	LI YS, LI S. Research progress and review on the mechanism of promoting blood circulation and removing blood stasis drugs in the prevention and treatment of thrombosis[C]// Proceedings of the Fifth National Academic Exchange Conference on the prevention and treatment of thrombosis by traditional Chinese medicine and the new election meeting of thrombosis branch of Chinese society of traditional Chinese medicine, 2011: 198-205. 李佑生, 黎帅. 活血化瘀药防治血栓病机制研究进展及述评[C]//第五次全国中医药防治血栓病学术交流会暨中华中医药学会血栓病分会换届改选工作会议论文集, 2011: 198-205.
[23]	ZHANG Y, HOU GM, LIU XM, et al. Study on the medication rule of containing insect drugs in the treatment of deep venous thrombosis based on data mining[J]. J Liaoning Univ Tradit Chin Med, 2021, 23(3): 1518. DOI: 10.13194/j.issn.1673-842x.2021.03.004. 张玥, 侯光敏, 刘效敏, 等. 基于数据挖掘含虫类药物组方治疗深静脉血栓形成的用药规律研究[J]. 辽宁中医药大学学报, 2021, 23(3): 1518. DOI: 10.13194/j.issn.1673-842x.2021.03.004.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (350) PDF downloads(46)

Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis

DOI: 10.3969/j.issn.1001-5256.2022.07.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of anti-liver fibrosis traditional Chinese medicine therapy on the prognosis of patients with liver cirrhosis and superior mesenteric venous thrombosis

DOI: 10.3969/j.issn.1001-5256.2022.07.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content